New therapeutic targets for calcific aortic valve stenosis: the lipoprotein(a)-lipoprotein-associated phospholipase A2-oxidized phospholipid axis.

@article{Hung2014NewTT,
  title={New therapeutic targets for calcific aortic valve stenosis: the lipoprotein(a)-lipoprotein-associated phospholipase A2-oxidized phospholipid axis.},
  author={Ming-yow Hung and Joseph L. Witztum and Sotirios Tsimikas},
  journal={Journal of the American College of Cardiology},
  year={2014},
  volume={63 5},
  pages={478-80}
}
Calcific aortic valve stenosis (CAVS) is the most common form of acquired valvular heart disease, present in 3% of the population more than 75 years of age (1). Although risk factors are similar for CAVS and atherosclerosis, w50% of patients with CAVS do not have clinically significant cardiovascular disease (CVD), suggesting related, but unique, pathophysiology (1). Although surgical aortic valve replacement remains the gold standard treatment for most patients, at least one-third of… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 29 references

Similar Papers

Loading similar papers…